Watch LGNXZ. Know when insiders buy.
One email the day a filing lands. Free.
LGNXZ
LIGAND PHARMACEUTICALS INC
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $290.5M +54.9%NET INCOME $197.2MNET DEBT $119.9M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $63.7M | +33.7% | — | $8.6M | $48.5M | +900.8% | 2.22 | $24M | $26K | $24M | Aug 7 |
| Q1 2026 · Mar 31 | $51.7M | +14.1% | — | $17.4M | −$13.3M | — | -0.67 | $48.7M | $228K | $48.5M | Aug 7 |
| Q4 2025 · Dec 31derived | $59.7M | +39.4% | — | $13.8M | $44.8M | — | 2.18 | $45.9M | $9K | $45.9M | Feb 27 |
| Q3 2025 · Sep 30 | $115.5M | +122.8% | — | $54.9M | $117.3M | — | 5.68 | $13.1M | $15K | $13.1M | Nov 7 |
| Q2 2025 · Jun 30 | $47.6M | +14.7% | — | $8.4M | $4.8M | — | 0.24 | $15.8M | $214K | $15.6M | Aug 7 |
| Q1 2025 · Mar 31 | $45.3M | +46.3% | — | −$36.2M | −$42.5M | −149.3% | -2.21 | −$25.4M | $214K | −$25.7M | May 8 |
| Q4 2024 · Dec 31derived | $42.8M | +52.4% | — | −$9.6M | −$31.1M | −270.9% | -1.68 | $28.5M | $712K | $27.8M | Feb 27 |
| Q3 2024 · Sep 30 | $51.8M | +57.6% | — | $3.1M | −$7.2M | — | -0.39 | $36.5M | $596K | $35.9M | Nov 7 |
| Q2 2024 · Jun 30 | $41.5M | — | — | −$19.1M | −$51.9M | — | -2.88 | $13.3M | $408K | $12.9M | Nov 7 |
| Q1 2024 · Mar 31 | $31M | — | — | $3M | $86.1M | — | 4.75 | $18.7M | $105K | $18.6M | Nov 7 |
| Q4 2023 · Dec 31derived | $28.1M | — | — | −$3.4M | $18.2M | — | 1.03 | $8.1M | $417K | $7.6M | Feb 27 |
| Q3 2023 · Sep 30 | $32.9M | — | — | $3.1M | −$10.3M | — | -0.59 | $7.6M | $487K | $7.2M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $268.1M | — | $41M | $124.5M | 46.4% | 6.13 | $49.4M | $452K | $48.9M | $15M | — |
| FY2024 · to Dec 31 | $167.1M | — | −$22.6M | −$4M | -2.4% | -0.22 | $97M | $1.8M | $95.2M | $0 | — |
| FY2023 · to Dec 31 | $131.3M | — | $11.9M | $52.2M | 39.7% | 2.94 | $49.6M | $3.5M | $46.1M | $0 | — |
| FY2022 · to Dec 31 | $196.2M | — | $3M | −$33.4M | -17.0% | -1.98 | $137.8M | $17.9M | $119.9M | $0 | — |
| FY2021 · to Dec 31 | $241.5M | — | $103.9M | $57.1M | 23.7% | 3.31 | $78.8M | $8.8M | $70M | $0 | — |
| FY2020 · to Dec 31 | $163.6M | — | $37.5M | −$3M | -1.8% | -0.18 | $54.6M | $4.5M | $50.1M | $78M | — |
Every number comes from LIGAND PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.